Krystal Biotech, Inc. (KRYS) Total liabilities 2021–2025
Krystal Biotech, Inc. (KRYS) total liabilities at each fiscal year-end, per SEC filings.
$114.2MFY2025 · since FY2021: $32.7M → $114.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $114.2M | +4.4% |
| FY2024 | $109.5M | +175.6% |
| FY2023 | $39.7M | +9.6% |
| FY2022 | $36.2M | +10.7% |
| FY2021 | $32.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More KRYS financial trends
KRYS RevenueKRYS Net incomeKRYS Net marginKRYS Gross profitKRYS Gross marginKRYS Operating incomeKRYS Operating marginKRYS Operating cash flowKRYS Free cash flowKRYS Capital expendituresKRYS Return on equityKRYS Stock buybacksKRYS Dividends paidKRYS Total assetsKRYS Shareholders’ equityKRYS overview →